EMILY SHAW

Provider status for pharmacists; implementation of the No Surprises Act, P.L. 116-260; sustainability of safety net health systems; social determinants of health; promoting coordinated care; FCCs COVID-19 Telehealth Program; support of telehealth policies, including for audio-only telehealth services; Hill-Burton funding for front line safety net hospitals in H.R.5376; within Inflation Reduction Act, P.L. 117-169, impact of pharmaceutical pricing policies on 340B drug discount program; S.3799, PREVENT Pandemics Act (social determinants of health provisions); policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R.2617, the Consolidated Appropriations Act, 2023.

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, The Consolidated Appropriations Act of 2021, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief and Economic Security (CARES) Act - issues impacting hospital financing, Medicaid DSH, telehealth expansion, Provider Relief Funds; H.R.266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; support for issues regarding recognition of uncompensated are costs and addressing social determinants of health in the Medicaid and Medicare populations; H.R.7292 - The COVID-19 Hospital Forgiveness Act; support of telehealth policies, including for audio-only telehealth services; H.R.5376 - Build Back Better Act, policies concerning Medicare graduate medical education (GME); H.R.7053/S.3792 - acute hospital care at home waiver flexibility; policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R.1868/Pub. L. No. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester; in general - protecting access to physician services for Medicare beneficiaries per preventing reductions resulting from Medicare sequestration, Statutory PAYGO, and reduction in Medicare conversion factor for CY2023; H.R.2617, the Consolidated Appropriations Act, 2023.

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, The Consolidated Appropriations Act of 2021, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief and Economic Security (CARES) Act - issues impacting hospital financing, Medicaid DSH, telehealth expansion, Provider Relief Funds; H.R.266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; support for issues regarding recognition of uncompensated are costs and addressing social determinants of health in the Medicaid and Medicare populations; H.R.7292 - The COVID-19 Hospital Forgiveness Act; support of telehealth policies, including for audio-only telehealth services; H.R.5376 - Build Back Better Act, policies concerning Medicare graduate medical education (GME); H.R.7053/S.3792 - acute hospital care at home waiver flexibility; policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R.1868/Pub. L. No. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester; in general - protecting access to physician services for Medicare beneficiaries per preventing reductions resulting from Medicare sequestration, Statutory PAYGO, and reduction in Medicare conversion factor for CY2023; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R.366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R.482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.2617, the Consolidated Appropriations Act, 2023.

Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, The Consolidated Appropriations Act of 2021, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief and Economic Security (CARES) Act - issues impacting hospital financing, Medicaid DSH, telehealth expansion, Provider Relief Funds; H.R.266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; support for issues regarding recognition of uncompensated are costs and addressing social determinants of health in the Medicaid and Medicare populations; H.R.7292 - The COVID-19 Hospital Forgiveness Act; support of telehealth policies, including for audio-only telehealth services; H.R.5376 - Build Back Better Act, policies concerning Medicare graduate medical education (GME); H.R.7053/S.3792 - acute hospital care at home waiver flexibility; policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R.1868/Pub. L. No. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester; in general - protecting access to physician services for Medicare beneficiaries per preventing reductions resulting from Medicare sequestration, Statutory PAYGO, and reduction in Medicare conversion factor for CY2023; H.R.2617, the Consolidated Appropriations Act, 2023.

S.464/H.R.2163, the Safe Step Act; H.R.1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers; issues related to coverage of products under drug formulary; policies reforming prior authorization of physician services; implementation of the No Surprises Act, P.L. 116-260; H.R.2617, the Consolidated Appropriations Act, 2023.

Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, The Consolidated Appropriations Act of 2021, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief and Economic Security (CARES) Act - issues impacting hospital financing, Medicaid DSH, telehealth expansion, Provider Relief Funds; H.R.266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; support for issues regarding recognition of uncompensated are costs and addressing social determinants of health in the Medicaid and Medicare populations; H.R.7292 - The COVID-19 Hospital Forgiveness Act; support of telehealth policies, including for audio-only telehealth services; H.R.5376 - Build Back Better Act, policies concerning Medicare graduate medical education (GME); H.R.7053/S.3792 - acute hospital care at home waiver flexibility; policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R.1868/Pub. L. No. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester; in general - protecting access to physician services for Medicare beneficiaries per preventing reductions resulting from Medicare sequestration, Statutory PAYGO, and reduction in Medicare conversion factor for CY2023; H.R.2617, the Consolidated Appropriations Act, 2023.

Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

S.464/H.R.2163, the Safe Step Act; H.R.1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers; issues related to coverage of products under drug formulary; policies reforming prior authorization of physician services; implementation of the No Surprises Act, P.L. 116-260; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R.366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases; H.R.2617, the Consolidated Appropriations Act, 2023.

Provider status for pharmacists; implementation of the No Surprises Act, P.L. 116-260; sustainability of safety net health systems; social determinants of health; promoting coordinated care; FCCs COVID-19 Telehealth Program; support of telehealth policies, including for audio-only telehealth services; Hill-Burton funding for front line safety net hospitals in H.R.5376; within Inflation Reduction Act, P.L. 117-169, impact of pharmaceutical pricing policies on 340B drug discount program; S.3799, PREVENT Pandemics Act (social determinants of health provisions); policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R.2617, the Consolidated Appropriations Act, 2023.

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, The Consolidated Appropriations Act of 2021, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief and Economic Security (CARES) Act - issues impacting hospital financing, Medicaid DSH, telehealth expansion, Provider Relief Funds; H.R.266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; support for issues regarding recognition of uncompensated are costs and addressing social determinants of health in the Medicaid and Medicare populations; H.R.7292 - The COVID-19 Hospital Forgiveness Act; support of telehealth policies, including for audio-only telehealth services; H.R.5376 - Build Back Better Act, policies concerning Medicare graduate medical education (GME); H.R.7053/S.3792 - acute hospital care at home waiver flexibility; policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R.1868/Pub. L. No. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester; in general - protecting access to physician services for Medicare beneficiaries per preventing reductions resulting from Medicare sequestration, Statutory PAYGO, and reduction in Medicare conversion factor for CY2023; H.R.2617, the Consolidated Appropriations Act, 2023.

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R.482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.2617, the Consolidated Appropriations Act, 2023.

S.464/H.R.2163, the Safe Step Act; H.R.1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers; issues related to coverage of products under drug formulary; policies reforming prior authorization of physician services; implementation of the No Surprises Act, P.L. 116-260; H.R.2617, the Consolidated Appropriations Act, 2023.

Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R.366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases; H.R.2617, the Consolidated Appropriations Act, 2023.

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R.482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R.482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.2617, the Consolidated Appropriations Act, 2023.

Provider status for pharmacists; implementation of the No Surprises Act, P.L. 116-260; sustainability of safety net health systems; social determinants of health; promoting coordinated care; FCCs COVID-19 Telehealth Program; support of telehealth policies, including for audio-only telehealth services; Hill-Burton funding for front line safety net hospitals in H.R.5376; within Inflation Reduction Act, P.L. 117-169, impact of pharmaceutical pricing policies on 340B drug discount program; S.3799, PREVENT Pandemics Act (social determinants of health provisions); policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R.2617, the Consolidated Appropriations Act, 2023.

Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

S.464/H.R.2163, the Safe Step Act; H.R.1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers; issues related to coverage of products under drug formulary; policies reforming prior authorization of physician services; implementation of the No Surprises Act, P.L. 116-260; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

S.464/H.R.2163, the Safe Step Act; H.R.1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers; issues related to coverage of products under drug formulary; policies reforming prior authorization of physician services; implementation of the No Surprises Act, P.L. 116-260; H.R.2617, the Consolidated Appropriations Act, 2023.

S. 464/H.R. 2163, the Safe Step Act; H.R. 1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers; issues related to coverage of products under drug formulary; policies reforming prior authorization of physician services; implementation of the No Surprises Act, P.L. 116-260.

Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.

Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.

Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases.

Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 1730/S.670, Speeding Therapy Access Today Act; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.

H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 1730/S.670, Speeding Therapy Access Today Act; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.

H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 1730/S.670, Speeding Therapy Access Today Act.

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); Medicare site neutrality policies; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, The Consolidated Appropriations Act of 2021, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief and Economic Security (CARES) Act - issues impacting hospital financing, Medicaid DSH, telehealth expansion, Provider Relief Funds; H.R. 266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; increase in FMAP funding per COVID-19 PHE; support for issues regarding recognition of uncompensated care costs and addressing social determinants of health in the Medicaid and Medicare populations; H.R. 7292 - The COVID-19 Hospital Forgiveness Act; support of telehealth policies, including for audio-only telehealth services; H.R. 5376 - Build Back Better Act, policies concerning Medicare graduate medical education (GME); H.R. 7053/S. 3792 - acute hospital care at home waiver flexibility; policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R. 1868/Pub. L. No. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester.

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, The Consolidated Appropriations Act of 2021, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief and Economic Security (CARES) Act - issues impacting hospital financing, Medicaid DSH, telehealth expansion, Provider Relief Funds; H.R. 266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; support for issues regarding recognition of uncompensated care costs and addressing social determinants of health in the Medicaid and Medicare populations; H.R. 7292 - The COVID-19 Hospital Forgiveness Act; support of telehealth policies, including for audio-only telehealth services; H.R. 5376 - Build Back Better Act, policies concerning Medicare graduate medical education (GME); H.R. 7053/S. 3792 - acute hospital care at home waiver flexibility; policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R. 1868/Pub. L. No. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester; in general - protecting access to physician services for Medicare beneficiaries per preventing reductions resulting from Medicare sequestration, Statutory PAYGO, and reduction in Medicare conversion factor for CY2023.

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, The Consolidated Appropriations Act of 2021, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief and Economic Security (CARES) Act - issues impacting hospital financing, Medicaid DSH, telehealth expansion, Provider Relief Funds; H.R.266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; support for issues regarding recognition of uncompensated care costs and addressing social determinants of health in the Medicaid and Medicare populations; H.R.7292 - The COVID-19 Hospital Forgiveness Act; support of telehealth policies, including for audio-only telehealth services; H.R.5376 - Build Back Better Act, policies concerning Medicare graduate medical education (GME); H.R.7053/S.3792 - acute hospital care at home waiver flexibility; policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R.1868/Pub. L. No. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester; in general - protecting access to physician services for Medicare beneficiaries per preventing reductions resulting from Medicare sequestration, Statutory PAYGO, and reduction in Medicare conversion factor for CY2023; H.R.2617, the Consolidated Appropriations Act, 2023.

Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.

Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.

Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases.

S.464/H.R.2163, the Safe Step Act; H.R.1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers; issues related to coverage of products under drug formulary; policies reforming prior authorization of physician services; implementation of the No Surprises Act, P.L. 116-260; H.R.2617, the Consolidated Appropriations Act, 2023.

S. 464/H.R. 2163, the Safe Step Act; H.R. 1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers; issues related to coverage of products under drug formulary; policies reforming prior authorization of physician services; implementation of the No Surprises Act, P.L. 116-260.

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R.482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.2617, the Consolidated Appropriations Act, 2023.

S.464/H.R.2163, the Safe Step Act; H.R.1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers; issues related to coverage of products under drug formulary; policies reforming prior authorization of physician services; implementation of the No Surprises Act, P.L. 116-260; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, The Consolidated Appropriations Act of 2021, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief and Economic Security (CARES) Act - issues impacting hospital financing, Medicaid DSH, telehealth expansion, Provider Relief Funds; H.R.266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; support for issues regarding recognition of uncompensated care costs and addressing social determinants of health in the Medicaid and Medicare populations; H.R.7292 - The COVID-19 Hospital Forgiveness Act; support of telehealth policies, including for audio-only telehealth services; H.R.5376 - Build Back Better Act, policies concerning Medicare graduate medical education (GME); H.R.7053/S.3792 - acute hospital care at home waiver flexibility; policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R.1868/Pub. L. No. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester; in general - protecting access to physician services for Medicare beneficiaries per preventing reductions resulting from Medicare sequestration, Statutory PAYGO, and reduction in Medicare conversion factor for CY2023; H.R.2617, the Consolidated Appropriations Act, 2023.

Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

Provider status for pharmacists; implementation of the No Surprises Act, P.L. 116-260; sustainability of safety net health systems; social determinants of health; promoting coordinated care; FCCs COVID-19 Telehealth Program; support of telehealth policies, including for audio-only telehealth services; Hill-Burton funding for front line safety net hospitals in H.R.5376; within Inflation Reduction Act, P.L. 117-169, impact of pharmaceutical pricing policies on 340B drug discount program; S.3799, PREVENT Pandemics Act (social determinants of health provisions); policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R.366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases; H.R.2617, the Consolidated Appropriations Act, 2023.

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, The Consolidated Appropriations Act of 2021, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief and Economic Security (CARES) Act - issues impacting hospital financing, Medicaid DSH, telehealth expansion, Provider Relief Funds; H.R.266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; support for issues regarding recognition of uncompensated care costs and addressing social determinants of health in the Medicaid and Medicare populations; H.R.7292 - The COVID-19 Hospital Forgiveness Act; support of telehealth policies, including for audio-only telehealth services; H.R.5376 - Build Back Better Act, policies concerning Medicare graduate medical education (GME); H.R.7053/S.3792 - acute hospital care at home waiver flexibility; policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R.1868/Pub. L. No. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester; in general - protecting access to physician services for Medicare beneficiaries per preventing reductions resulting from Medicare sequestration, Statutory PAYGO, and reduction in Medicare conversion factor for CY2023; H.R.2617, the Consolidated Appropriations Act, 2023.

COPE Act of 2019, H.R. 1528; American Rescue Plan, importance of 340B drug pricing program; Provider status for pharmacists; surprise medical billing in general; sustainability of safety net health systems; social determinants of health; promoting coordinated care; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act; The Consolidated Appropriations Act of 2021; the Families First Coronavirus Response Act (FFCRA); the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues regarding patient care, Provider Relief Funds; and H.R. 266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; and FCCs COVID-19 Telehealth Program; support of telehealth policies, including for audio-only telehealth services; Hill-Burton funding for front line safety net hospitals in H.R. 5376; within H.R.5376 impact of pharmaceutical pricing policies on 340B drug discount program; S. 3799, PREVENT Pandemics Act (social determinants of health provisions).

COPE Act of 2019, H.R. 1528; American Rescue Plan, importance of 340B drug pricing program; Provider status for pharmacists; surprise medical billing in general; sustainability of safety net health systems; social determinants of health; promoting coordinated care; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act; The Consolidated Appropriations Act of 2021; the Families First Coronavirus Response Act (FFCRA); the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues regarding patient care, Provider Relief Funds; and H.R. 266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; and FCCs COVID-19 Telehealth Program; support of telehealth policies, including for audio-only telehealth services; Hill-Burton funding for front line safety net hospitals in H.R. 5376; within H.R.5376 impact of pharmaceutical pricing policies on 340B drug discount program; S. 3799, PREVENT Pandemics Act (social determinants of health provisions); policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs.

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); Medicare site neutrality policies; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, The Consolidated Appropriations Act of 2021, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief and Economic Security (CARES) Act - issues impacting hospital financing, Medicaid DSH, telehealth expansion, Provider Relief Funds; H.R. 266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; increase in FMAP funding per COVID-19 PHE; support for issues regarding recognition of uncompensated care costs and addressing social determinants of health in the Medicaid and Medicare populations; H.R. 7292 - The COVID-19 Hospital Forgiveness Act; support of telehealth policies, including for audio-only telehealth services; H.R. 5376 - Build Back Better Act, policies concerning Medicare graduate medical education (GME); H.R. 7053/S. 3792 - acute hospital care at home waiver flexibility.

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); Medicare site neutrality policies; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, The Consolidated Appropriations Act of 2021, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief and Economic Security (CARES) Act - issues impacting hospital financing, Medicaid DSH, telehealth expansion, Provider Relief Funds; H.R. 266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; increase in FMAP funding per COVID-19 PHE; support for issues regarding recognition of uncompensated care costs and addressing social determinants of health in the Medicaid and Medicare populations; H.R. 7292 - The COVID-19 Hospital Forgiveness Act; support of telehealth policies, including for audio-only telehealth services; H.R. 5376 - Build Back Better Act, policies concerning Medicare graduate medical education (GME); H.R. 7053/S. 3792 - acute hospital care at home waiver flexibility; policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R. 1868/Pub. L. No. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester.

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, The Consolidated Appropriations Act of 2021, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief and Economic Security (CARES) Act - issues impacting hospital financing, Medicaid DSH, telehealth expansion, Provider Relief Funds; H.R. 266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; support for issues regarding recognition of uncompensated care costs and addressing social determinants of health in the Medicaid and Medicare populations; H.R. 7292 - The COVID-19 Hospital Forgiveness Act; support of telehealth policies, including for audio-only telehealth services; H.R. 5376 - Build Back Better Act, policies concerning Medicare graduate medical education (GME); H.R. 7053/S. 3792 - acute hospital care at home waiver flexibility; policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R. 1868/Pub. L. No. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester; in general - protecting access to physician services for Medicare beneficiaries per preventing reductions resulting from Medicare sequestration, Statutory PAYGO, and reduction in Medicare conversion factor for CY2023.

Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.

Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.

Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases.

H.R. 366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 5376 - Build Back Better Act, issues related to Medicare Part B and Part D drug policies.

H.R. 366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases.

H.R.366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R. 366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 5376 - Build Back Better Act, issues related to Medicare Part B and Part D drug policies.

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R. 482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases.

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R.482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.2617, the Consolidated Appropriations Act, 2023.

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R. 482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases.

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R. 482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases.

COPE Act of 2019, H.R. 1528; American Rescue Plan, importance of 340B drug pricing program; Provider status for pharmacists; surprise medical billing in general; sustainability of safety net health systems; social determinants of health; promoting coordinated care; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act; The Consolidated Appropriations Act of 2021; the Families First Coronavirus Response Act (FFCRA); the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues regarding patient care, Provider Relief Funds; and H.R. 266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; and FCCs COVID-19 Telehealth Program; support of telehealth policies, including for audio-only telehealth services; Hill-Burton funding for front line safety net hospitals in H.R. 5376; within H.R.5376 impact of pharmaceutical pricing policies on 340B drug discount program; S. 3799, PREVENT Pandemics Act (social determinants of health provisions).

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); Medicare site neutrality policies; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, The Consolidated Appropriations Act of 2021, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief and Economic Security (CARES) Act - issues impacting hospital financing, Medicaid DSH, telehealth expansion, Provider Relief Funds; H.R. 266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; increase in FMAP funding per COVID-19 PHE; support for issues regarding recognition of uncompensated care costs and addressing social determinants of health in the Medicaid and Medicare populations; H.R. 7292 - The COVID-19 Hospital Forgiveness Act; support of telehealth policies, including for audio-only telehealth services; H.R. 5376 - Build Back Better Act, policies concerning Medicare graduate medical education (GME); H.R. 7053/S. 3792 - acute hospital care at home waiver flexibility; policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R. 1868/Pub. L. No. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester.

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, The Consolidated Appropriations Act of 2021, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief and Economic Security (CARES) Act - issues impacting hospital financing, Medicaid DSH, telehealth expansion, Provider Relief Funds; H.R. 266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; support for issues regarding recognition of uncompensated care costs and addressing social determinants of health in the Medicaid and Medicare populations; H.R. 7292 - The COVID-19 Hospital Forgiveness Act; support of telehealth policies, including for audio-only telehealth services; H.R. 5376 - Build Back Better Act, policies concerning Medicare graduate medical education (GME); H.R. 7053/S. 3792 - acute hospital care at home waiver flexibility; policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R. 1868/Pub. L. No. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester; in general - protecting access to physician services for Medicare beneficiaries per preventing reductions resulting from Medicare sequestration, Statutory PAYGO, and reduction in Medicare conversion factor for CY2023.

COPE Act of 2019, H.R. 1528; American Rescue Plan, importance of 340B drug pricing program; Provider status for pharmacists; surprise medical billing in general; sustainability of safety net health systems; social determinants of health; promoting coordinated care; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act; The Consolidated Appropriations Act of 2021; the Families First Coronavirus Response Act (FFCRA); the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues regarding patient care, Provider Relief Funds; and H.R. 266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; and FCCs COVID-19 Telehealth Program; support of telehealth policies, including for audio-only telehealth services; Hill-Burton funding for front line safety net hospitals in H.R. 5376; within H.R.5376 impact of pharmaceutical pricing policies on 340B drug discount program; S. 3799, PREVENT Pandemics Act (social determinants of health provisions); policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs.

H.R. 366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 5376 - Build Back Better Act, issues related to Medicare Part B and Part D drug policies.

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, The Consolidated Appropriations Act of 2021, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief and Economic Security (CARES) Act - issues impacting hospital financing, Medicaid DSH, telehealth expansion, Provider Relief Funds; H.R.266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; support for issues regarding recognition of uncompensated care costs and addressing social determinants of health in the Medicaid and Medicare populations; H.R.7292 - The COVID-19 Hospital Forgiveness Act; support of telehealth policies, including for audio-only telehealth services; H.R.5376 - Build Back Better Act, policies concerning Medicare graduate medical education (GME); H.R.7053/S.3792 - acute hospital care at home waiver flexibility; policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R.1868/Pub. L. No. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester; in general - protecting access to physician services for Medicare beneficiaries per preventing reductions resulting from Medicare sequestration, Statutory PAYGO, and reduction in Medicare conversion factor for CY2023; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R.366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases; H.R.2617, the Consolidated Appropriations Act, 2023.

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); Medicare site neutrality policies; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, The Consolidated Appropriations Act of 2021, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief and Economic Security (CARES) Act - issues impacting hospital financing, Medicaid DSH, telehealth expansion, Provider Relief Funds; H.R. 266/P.L. 116-139, the Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund; increase in FMAP funding per COVID-19 PHE; support for issues regarding recognition of uncompensated care costs and addressing social determinants of health in the Medicaid and Medicare populations; H.R. 7292 - The COVID-19 Hospital Forgiveness Act; support of telehealth policies, including for audio-only telehealth services; H.R. 5376 - Build Back Better Act, policies concerning Medicare graduate medical education (GME); H.R. 7053/S. 3792 - acute hospital care at home waiver flexibility.

Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

Provider status for pharmacists; implementation of the No Surprises Act, P.L. 116-260; sustainability of safety net health systems; social determinants of health; promoting coordinated care; FCCs COVID-19 Telehealth Program; support of telehealth policies, including for audio-only telehealth services; Hill-Burton funding for front line safety net hospitals in H.R.5376; within Inflation Reduction Act, P.L. 117-169, impact of pharmaceutical pricing policies on 340B drug discount program; S.3799, PREVENT Pandemics Act (social determinants of health provisions); policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R. 366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases.

H.R. 366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 5376 - Build Back Better Act, issues related to Medicare Part B and Part D drug policies.

Provider status for pharmacists; implementation of the No Surprises Act, P.L. 116-260; sustainability of safety net health systems; social determinants of health; promoting coordinated care; FCCs COVID-19 Telehealth Program; support of telehealth policies, including for audio-only telehealth services; Hill-Burton funding for front line safety net hospitals in H.R. 5376; within Inflation Reduction Act, P.L. 117-169, impact of pharmaceutical pricing policies on 340B drug discount program; S. 3799, PREVENT Pandemics Act (social determinants of health provisions); policy proposals to address mental and physical/medical comorbidities of beneficiaries in the Medicare/Medicaid programs.

Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.

Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.

Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.

H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 1730/S.670, Speeding Therapy Access Today Act; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.

Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.

H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 1730/S.670, Speeding Therapy Access Today Act; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.